The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Their mission includes:
Phages and phage-borne enzymes as new antibacterial agents.
McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.
Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023
Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.
Global Clinical Phage Rounds 8
Lessons learned (so far) from treating patients with phage therapy for antibiotic-resistant bacterial infections
Global Clinical Phage Rounds 7
Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter
Global Clinical Phage Rounds 6
The French Experience
Global Clinical Phage Rounds 5
Case Discussion – How long is enough: duration of phage therapy for NTM infections in three Australian patients?
Global Clinical Phage Rounds 4
Belgian Published cases
Global Clinical Phage Rounds 3
Case Discussion – Urgent cases on Mycobacterium
Global Clinical Phage Rounds 2
Case Discussion – Renal transplant and recurrent UTIs
ESGNTA as part of the VOM2023 conference
7 July 2023, The George Eliava Institute of Bacteriophages, Tbilisi, Georgia Congress
If you have questions or comments for our study group, we warmly invite you to contact us!
